Meet Omar Wahab, Head of Fire Processing, Lonza Bioscience. He highlights Lonza’s 30-year cell culture media legacy, the new TheraPEAK platform for AAV/HEK workflows, an FDA-approved cytokine supplement used in 130+ trials.
He also outlines Lonza’s innovation approach: strong internal R&D, partnerships with CDMOs, and recent inorganic growth through the acquisition of Redberry.
Watch the full interview to hear more about these advances and what they mean for the future of cell therapy manufacturing.